EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, headquartered in Watertown, Massachusetts, specializes in sustained-release drug delivery systems for eye diseases and other chronic conditions, offering products like DEXYCU and developing treatments such as EYP-1901.
Company Overview
EyePoint Pharmaceuticals is a specialty biopharmaceutical company headquartered in Watertown, Massachusetts. The company focuses on the development of sustained-release drug delivery systems to treat debilitating diseases of the eye and other localized, chronic conditions. EyePoint Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol 'EYPT'.
Products
EyePoint Pharmaceuticals offers several innovative products, including DEXYCU, an FDA-approved treatment for inflammation following ocular surgery. The company is also developing a promising new drug, EYP-1901, which is a potential treatment for serious retinal diseases such as wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, the company has a portfolio of U.S. patents protecting these products, including those for YUTIQ and DEXYCU.
Drug Delivery Technologies
EyePoint Pharmaceuticals utilizes advanced proprietary technologies for drug delivery, including DURASERT and VERISOME. These technologies enable the sustained release of medication over extended periods, which is crucial for treating chronic conditions. DURASERT and VERISOME are instrumental in the effectiveness and commercialization of EyePoint’s product offerings, such as DEXYCU and potentially EYP-1901.
Pipeline Development
EyePoint Pharmaceuticals is actively involved in the development of new treatments for debilitating eye diseases. One of their leading pipeline products is EYP-1901, which is under development as a potential treatment for retinal conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. This product is set to address significant unmet medical needs in the field of ophthalmology.
